Skip to content

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02703857
Acronym
PROPHYLOXITINE
Enrollment
12
Registered
2016-03-09
Start date
2016-02-29
Completion date
2016-09-20
Last updated
2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Prophylaxis Surgery

Brief summary

The surgical site infection is one of the most important causes of postoperative morbidity. The appropriate antibiotic prophylaxis is one of the most effective ways to prevent surgical site infections. The recommendations of the French Society of Anesthesia Resuscitation on antibiotic prophylaxis in long surgeries are based on low documentation, including frequency and dosage of reinjection. The main objective of the study is to describe the tissue and plasma pharmacokinetics of cefoxitin after repeated injections. This is an open monocentric study (phase 4) including adults aged 18 to 80 years in need of major abdominal surgery whose foreseeable time exceeds 4 hours and justifying an antibiotic prophylaxis by cefoxitin. They receive 2 g cefoxitin parenterally at least 30 minutes before the incision and then every 2 hours until closing. The primary endpoints are: * Total and plasma free concentrations of cefoxitin 0, 10, 30, 60, 90, 120 minutes after start of each infusion cefoxitin * Tissue free concentrations of cefoxitin every 20 minutes after the start of the first infusion cefoxitin until skin closure * Urinary concentrations of cefoxitin

Interventions

Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing

Sponsors

Poitiers University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who underwent major abdominal surgery whose forseeable time exceeds 4 hours and requires an antibiotic prophylaxis by cefoxitin

Exclusion criteria

* morbid obesity (BMI \> 35 kg/m²) * severe renal impairment (clearance creatinine \< 30ml/min) * beta lactam hypersensitivity * pregnancy

Design outcomes

Primary

MeasureTime frame
Total and free plasma of cefoxitin after repeated injections48 hours
Free tissue concentration of cefoxitin every 20 minutes after the beginning of injections48 hours
Concentration of cefoxitin in urine after every injection48 hours

Secondary

MeasureTime frame
Clearance of elimination of cefoxitin48 hours
Cmax of Cefoxitin48 hours
Percentage of time when tissue concentration of cefoxitin is higher than the minimal inhibitory concentration of target organisms48 hours
Area under the curve of plasma and tissue concentration of cefoxitin48 hours
Vd of distribution o cefoxitin48 hours
Concentrations of antibiotic in peritoneal fluid48 hours
Clearance of distribution of cefoxitin48 hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026